# EDGAR Filing Document

**Accession Number:** 0000722313
**File Stem:** 0001493152-26-022752
**Filing Date:** 2026-5
**Character Count:** 77881
**Document Hash:** adef53f449237685ebad6770223bf17d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-022752.hdr.sgml**: 20260513

**ACCESSION NUMBER**: 0001493152-26-022752

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 70

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260513

**DATE AS OF CHANGE**: 20260513

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NORTECH SYSTEMS INC
- **CENTRAL INDEX KEY:** 0000722313
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTRONIC COMPONENTS, NEC [3679]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 411681094
- **STATE OF INCORPORATION:** MN
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-13257
- **FILM NUMBER:** 26973910

**BUSINESS ADDRESS:**
- **STREET 1:** 7550 MERIDIAN CIRCLE N
- **STREET 2:** SUITE 150
- **CITY:** MAPLE GROVE
- **STATE:** MN
- **ZIP:** 55369
- **BUSINESS PHONE:** 952-345-2244

**MAIL ADDRESS:**
- **STREET 1:** 7550 MERIDIAN CIRCLE N
- **STREET 2:** SUITE 150
- **CITY:** MAPLE GROVE
- **STATE:** MN
- **ZIP:** 55369

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DSC NORTECH INC
- **DATE OF NAME CHANGE:** 19901217

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DIGIGRAPHIC SYSTEMS CORP
- **DATE OF NAME CHANGE:** 19881113

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D. C. 20549**

**FORM 10-Q**

**(Mark One)**

&nbsp;&nbsp;&nbsp;&nbsp;**☒** **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the quarterly period ended March 31, 2026**

**OR**

**☐** **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**NORTECH SYSTEMS INCORPORATED**

Commission file number **0-13257**

State of Incorporation: **Minnesota**

IRS Employer Identification No. **41-1681094**

Executive Offices: **7550 Meridian Circle N., Suite # 150, Maple Grove, MN 55369**

Telephone number: **(952) 345-2244**

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $.01 per share | NSYS | NASDAQ Capital Market |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes **☒** No **☐**

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulations S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes **☒** No **☐**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | |
|:---|:---|
| Large Accelerated Filer **☐** | Accelerated Filer ☐ |
| Non-accelerated Filer **☒** | Smaller Reporting Company **☒** |
| Emerging growth company **☐** |  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. **☐**

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes **☐** No **☒**

Number of shares of $0.01 par value common stock outstanding as of May 6, 2026 was 2,794,534.

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
|  | PAGE |
| **[PART I – FINANCIAL INFORMATION](#a_001)** |  |
| &nbsp;&nbsp;&nbsp;[Item 1 - Financial Statements](#a_002) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)](#a_003) | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Condensed Consolidated Balance Sheets](#a_004) | 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Condensed Consolidated Statements of Cash Flows](#a_005) | 5-6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Condensed Consolidated Statements of Shareholders' Equity](#a_007) | 7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Notes to Condensed Consolidated Financial Statements](#a_008) | 8-17 |
| &nbsp;&nbsp;&nbsp;[Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations](#sd_001) | 18 |
| &nbsp;&nbsp;&nbsp;[Item 3 - Quantitative and Qualitative Disclosures About Market Risk](#sd_002) | 22 |
| &nbsp;&nbsp;&nbsp;[Item 4 - Controls and Procedures](#sd_003) | 22 |
| **[PART II – OTHER INFORMATION](#sd_004)** |  |
| &nbsp;&nbsp;&nbsp;[Item 1 - Legal Proceedings](#sd_005) | 23 |
| &nbsp;&nbsp;&nbsp;[Item 1A. - Risk Factors](#sd_006) | 23 |
| &nbsp;&nbsp;&nbsp;[Item 2 - Unregistered Sales of Equity Securities, Use of Proceeds](#sd_007) | 23 |
| &nbsp;&nbsp;&nbsp;[Item 3 - Defaults on Senior Securities](#sd_008) | 23 |
| &nbsp;&nbsp;&nbsp;[Item 4 - Mine Safety Disclosures](#sd_009) | 23 |
| &nbsp;&nbsp;&nbsp;[Item 5 - Other Information](#sd_010) | 23 |
| &nbsp;&nbsp;&nbsp;[Item 6 - Exhibits](#sd_011) | 23 |
| &nbsp;&nbsp;&nbsp;[SIGNATURES](#sd_012) | 24 |

---

**PART I**

**ITEM 1. FINANCIAL STATEMENTS**

**NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**AND COMPREHENSIVE INCOME (LOSS)**

**(UNAUDITED)**

**(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)**

---

| | | |
|:---|:---|:---|
|  | **THREE MONTHS ENDED** | **THREE MONTHS ENDED** |
|  | **MARCH 31,** | **MARCH 31,** |
|  | **2026** | **2025** |
| Net sales | $30316 | $26895 |
| Cost of goods sold | 25614 | 23817 |
| Gross profit | 4702 | 3078 |
| Operating expenses: |  |  |
| &nbsp;&nbsp;&nbsp;Selling | 1331 | 1184 |
| &nbsp;&nbsp;&nbsp;General and administrative | 3014 | 2915 |
| &nbsp;&nbsp;&nbsp;Research and development | 310 | 326 |
| &nbsp;&nbsp;&nbsp;Restructuring charges | - | 266 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 4655 | 4691 |
| Income (loss) from operations | 47 | (1613) |
| Other expense: |  |  |
| &nbsp;&nbsp;&nbsp;Interest expense, net | (256) | (214) |
| Loss before income taxes | (209) | (1827) |
| Income tax benefit | (175) | (511) |
| Net loss | $(34) | $(1316) |
| Net loss per common share: |  |  |
| Basic (in dollars per share) | $(0.01) | $(0.48) |
| Weighted average number of common shares outstanding - basic (in shares) | 2786134 | 2760929 |
| Diluted (in dollars per share) | $(0.01) | $(0.48) |
| Weighted average number of common shares outstanding - diluted (in shares) | 2786134 | 2760929 |
| Other comprehensive income (loss) |  |  |
| &nbsp;&nbsp;&nbsp;Foreign currency translation | 69 | 6 |
| Comprehensive income (loss), net of tax | $35 | $(1310) |

---

*See Accompanying Notes to Condensed Consolidated Financial Statements.*

**NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**AS OF MARCH 31, 2026 AND DECEMBER 31, 2025**

**(UNAUDITED)**

**(IN THOUSANDS, EXCEPT SHARE DATA)**

---

| | | |
|:---|:---|:---|
|  | **MARCH 31,**<br> **2026** | **DECEMBER 31,**<br> **2025** |
| **ASSETS** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;Cash | $1964 | $1655 |
| &nbsp;&nbsp;&nbsp;Restricted cash | 244 |  |
| &nbsp;&nbsp;&nbsp;Accounts receivable, less allowance for credit losses of $205 and $161, respectively | 17823 | 16998 |
| &nbsp;&nbsp;&nbsp;Inventories, net | 23561 | 20695 |
| &nbsp;&nbsp;&nbsp;Contract assets | 16010 | 15184 |
| &nbsp;&nbsp;&nbsp;Prepaid assets and other assets | 1071 | 1618 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 60673 | 56150 |
| Property and equipment, net | 5077 | 5203 |
| Operating lease assets, net | 6720 | 7016 |
| Deferred tax assets | 3753 | 3394 |
| Other intangible assets, net | 151 | 156 |
| Deferred line of credit issuance costs | 266 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $76640 | $71919 |
| **LIABILITIES AND SHAREHOLDERS' EQUITY** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Lines of credit | $7485 | $7000 |
| &nbsp;&nbsp;&nbsp;Current portion of term loan | 433 |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | 14645 | 12809 |
| &nbsp;&nbsp;&nbsp;Accrued payroll and commissions | 2708 | 1822 |
| &nbsp;&nbsp;&nbsp;Customer deposits | 4672 | 5386 |
| &nbsp;&nbsp;&nbsp;Current portion of operating leases | 1309 | 1332 |
| &nbsp;&nbsp;&nbsp;Current portion of finance lease obligations | 259 | 274 |
| &nbsp;&nbsp;&nbsp;Other accrued liabilities | 1487 | 1221 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 32998 | 29844 |
| Long-term liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Term loan | 1743 |  |
| &nbsp;&nbsp;&nbsp;Long-term operating lease obligations | 6186 | 6476 |
| &nbsp;&nbsp;&nbsp;Long-term finance lease obligations | 577 | 626 |
| &nbsp;&nbsp;&nbsp;Other long-term liabilities | 428 | 426 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total long-term liabilities | 8934 | 7528 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 41932 | 37372 |
| Shareholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;Preferred stock, $1 par value; 1,000,000 shares authorized; 250,000 shares issued and outstanding | 250 | 250 |
| &nbsp;&nbsp;&nbsp;Common stock - $0.01 par value; 9,000,000 shares authorized; 2,786,134 and 2,786,134 shares issued and outstanding, respectively | 28 | 28 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 17981 | 17855 |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (640) | (709) |
| &nbsp;&nbsp;&nbsp;Retained earnings | 17089 | 17123 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total shareholders' equity | 34708 | 34547 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and shareholders' equity | $76640 | $71919 |

---

*See Accompanying Notes to Condensed Consolidated Financial Statements*.

**NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(UNAUDITED)**

**(IN THOUSANDS)**

---

| | | |
|:---|:---|:---|
|  | **THREE MONTHS ENDED** | **THREE MONTHS ENDED** |
|  | **MARCH 31,** | **MARCH 31,** |
|  | **2026** | **2025** |
| **CASH FLOWS FROM OPERATING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;Net loss | $(34) | $(1316) |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 303 | 347 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compensation on stock-based awards | 126 | 118 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in allowance for credit losses | 44 | 35 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in inventory reserves | (257) | 231 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred taxes | (359) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in current operating items: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (822) | (814) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (2610) | 487 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contract assets | (826) | 388 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | 460 | (1588) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 1917 | (1441) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued payroll and commissions | 883 | 674 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Customer deposits | (713) | (112) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other accrued liabilities | 327 | 61 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities | (1561) | (2930) |
| **CASH FLOWS FROM INVESTING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of property and equipment | (228) | (268) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (228) | (268) |
| **CASH FLOWS FROM FINANCING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from lines of credit | 9960 | 25970 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments to line of credit | (9472) | (22710) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from term loan | 2200 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments of debt issuance costs | (290) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from notes payable |  | 219 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Principal payments on financing leases | (62) | (52) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock award exercises | - | 19 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities | 2336 | 3446 |
| Effect of exchange rate changes on cash and restricted cash | 6 | (2) |
| Net change in cash and restricted cash | 553 | 246 |
| Cash and restricted cash - beginning of period | 1655 | 916 |
| Cash and restricted cash - end of period | $2208 | $1162 |
| Reconciliation of cash and restricted cash reported within the condensed consolidated balance sheets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash | $1964 | $1162 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted cash | 244 | - |
| Total cash and restricted cash reported in the condensed consolidated statements of cash flows | $2208 | $1162 |

---

**NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(UNAUDITED)**

**(IN THOUSANDS)**

---

| | | |
|:---|:---|:---|
|  | **THREE MONTHS ENDED** | **THREE MONTHS ENDED** |
|  | **MARCH 31,** | **MARCH 31,** |
|  | **2026** | **2025** |
| Supplemental disclosure of cash flow information: |  |  |
| &nbsp;&nbsp;&nbsp;Cash paid for interest | $167 | $203 |
| &nbsp;&nbsp;&nbsp;Cash (received) paid for income taxes | $(325) | $179 |
| Supplemental noncash investing and financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;Property and equipment purchases in accounts payable | $16 | $42 |

---

*See Accompanying Notes to Condensed Consolidated Financial Statements.*

**NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY**

**(UNAUDITED)**

**(IN THOUSANDS)**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Preferred Stock** | **Preferred Stock** | **Common Stock** | **Common Stock** | | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** |<br>**Additional**<br>**Paid-In**<br>**Capital** | **Accumulated**<br>**Other**<br>**Comprehensive**<br>**Loss** |<br>**Retained**<br>**Earnings** |<br>**Total**<br>**Shareholders'**<br>**Equity** |
| **Balance as of December 31, 2024** | 250 | $250 | 2761 | $28 | $17329 | $(977) | $17375 | $34005 |
| Net loss |  |  |  |  |  |  | (1316) | (1316) |
| Foreign currency translation adjustment |  |  |  |  |  | 6 |  | 6 |
| Stock option exercises |  |  |  |  | 19 |  |  | 19 |
| Compensation on stock-based awards | - | - | - | - | 118 | - | - | 118 |
| **Balance as of March 31, 2025** | 250 | $250 | 2761 | $28 | $17466 | $(971) | $16059 | $32832 |
| **Balance as of December 31, 2025** | 250 | $250 | 2786 | $28 | $17855 | $(709) | $17123 | $34547 |
| Net loss |  |  |  |  |  |  | (34) | (34) |
| Foreign currency translation adjustment |  |  |  |  |  | 69 |  | 69 |
| Compensation on stock-based awards | - | - | - | - | 126 | - | - | 126 |
| **Balance as of March 31, 2026** | 250 | $250 | 2786 | $28 | $17981 | $(640) | $17089 | $34708 |

---

*See Accompanying Notes to Condensed Consolidated Financial Statements.*

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(DOLLARS IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)**

**(UNAUDITED)**

**NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

***Basis of Presentation and Principles of Consolidation***

The accompanying unaudited condensed consolidated financial statements for the interim periods have been prepared in accordance with Generally Accepted Accounting Principles in the United States of America ("U.S. GAAP") for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Accordingly, the Company has omitted footnote disclosures that would substantially duplicate the disclosures contained in the Company's audited consolidated financial statements. These unaudited condensed consolidated financial statements should be read together with the audited consolidated financial statements for the year ended December 31, 2025, and notes thereto included in our Annual Report on Form 10-K as filed with the SEC.

The condensed consolidated financial statements include the accounts of Nortech Systems Incorporated and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. All dollar amounts are stated in thousands of U.S. dollars.

***Use of Estimates***

The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements. Estimates also affect the reported amounts of net sales and expenses during each reporting period. Significant items subject to estimates and assumptions include the lower of cost or net realizable value reserves for inventories, allowance for credit losses, realizability of deferred tax assets and long-lived asset recovery. Actual results could differ from those estimates.

***Tarriff Legislation***

 ****

In February 2026, the U.S. Supreme Court ruled that the International Emergency Economic Powers Act ("IEEPA") does not authorize the President to impose tariffs, resulting in the termination of all IEEPA-based tariffs effective February 24, 2026. Following this ruling, the Administration imposed a temporary 10% global tariff on most imported products under Section 122 of the Trade Expansion Act of 1962, effective February 24, 2026, for a 150-day period.

These new tariffs apply broadly to manufactured goods and component parts. The Company is evaluating the potential impact of these tariff actions on future material costs and sourcing decisions. The Company is actively seeking reimbursement of IEEPA tariffs from the federal government and the Company's vendors.

***Recently Issued New Accounting Standards***

 ****

In November 2024, the FASB issued ASU No. 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): *Disaggregation of Income Statement Expenses* ("ASU No. 2024-03"), which requires disaggregated expense information in the notes to the financial statements related to purchases of inventory, employee compensation, depreciation, intangible asset amortization and selling expenses for each statement of earnings line item that contains those expenses. ASU No. 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The guidance is to be applied on a prospective basis with the option to apply the standard retrospectively; this ASU allows for early adoption. The Company is currently evaluating the impact of this ASU on its consolidated financial statements disclosures.

***Adoption of New Accounting Standard***

In July 2025, the FASB issued ASU 2025-05, Financial Instruments – Credit Losses (Topic 326): *Measurement of Credit Losses for Accounts Receivable and Contract Assets* ("ASU No. 2025-05"), which reduces the complexity of applying credit losses to current accounts receivable and current contract assets arising from transactions accounted for under Topic 606 (revenue from contracts with customers). ASU 2025-05 is effective for annual and interim reporting periods beginning after December 15, 2025. The Company has adopted this ASU and it did not have a material impact on the consolidated financial statements.

***Restricted Cash***

Cash classified as restricted cash on our consolidated balance sheets relates to contractual cash dominion provisions under the Company's financing arrangements, which at March 31, 2026 were governed by the new Associated Bank facility. As of March 31, 2026 and December 31, 2025, we had restricted cash of $244 and $0, respectively.

The restricted cash balance at March 31, 2026 primarily represents customer deposits that are temporarily restricted due to timing at period end and are subject to the cash dominion provisions of the financing arrangement. These customer deposits are applied against the Company's line of credit on the next business day.

***Inventories***

Inventories are as follows:

---

| | | |
|:---|:---|:---|
|  | **March 31,**<br>**2026** | **December 31,**<br>**2025** |
| Raw materials | $23015 | $20575 |
| Work in process | 1290 | 1003 |
| Finished goods | 852 | 970 |
| Reserves | (1596) | (1853) |
| Inventories, net | $23561 | $20695 |

---

***Other Intangible Assets***

Other intangible assets as of March 31, 2026 and December 31, 2025 are as follows:

---

| | |
|:---|:---|
|  | **Patents** |
| Balances as of December 31, 2025 | $156 |
| &nbsp;&nbsp;&nbsp;Amortization | (5) |
| Balances as of March 31, 2026 | $151 |

---

Intangible assets are amortized on a straight-line basis over their estimated useful lives. The weighted average remaining amortization period of our intangible assets is 3.8 years. Of the patents' value as of March 31, 2026, $67 are being amortized and $84 are in process and a patent has not yet been issued.

Amortization expense of finite life intangible assets for the three months ended March 31, 2026 and 2025 was $5 and $5, respectively.

As of March 31, 2026, estimated future annual amortization expense related to these assets is as follows:

---

| | |
|:---|:---|
| **Year** | **Amount** |
| Remainder of 2026 | $14 |
| 2027 | 18 |
| 2028 | 18 |
| 2029 | 12 |
| 2030 | 4 |
| Thereafter | 1 |
| Total | $67 |

---

***Property and Equipment***

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. At March 31, 2026, the Company determined that no triggering events existed that would require an impairment assessment.

**NOTE 2. CONCENTRATION OF CREDIT RISK AND MAJOR CUSTOMERS**

Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash, accounts receivable, and contract assets. We maintain our excess cash balances in checking accounts primarily at two financial institutions, one in the United States and one in China. The account in the United States may at times exceed federally insured limits. The Company's $1,964 cash balance as of March 31, 2026, included approximately $612 and $78 that was held at banks located in China and Mexico, respectively. We grant credit to customers in the normal course of business and generally do not require collateral on our accounts receivable.

We have certain customers whose revenue individually represented 10% or more of net sales, or whose accounts receivable balances or contract asset balances individually represented 10% or more of gross accounts receivable.

Customers who represent 10% or more of net sales for the three months ended March 31, 2026 and 2025 are as follows:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended**<br> **March 31,** | **Three Months Ended**<br> **March 31,** |
|  | **2026** | **2025** |
| Customer A | 32% | 31% |
| Customer B | 13% | 11% |
| Total | 45% | 42% |

---

Customers who represent 10% or more of accounts receivable and contract assets for the periods ended March 31, 2026 and December 31, 2025 are as follows:

---

| | | |
|:---|:---|:---|
|  | **Accounts Receivable** | **Accounts Receivable** |
|  | **March 31,**<br> **2026** | **December 31,**<br> **2025** |
| Customer A | 26% | 20% |

---

SCHEDULE OF CONTRACT ASSETS CONCENTRATION OF CREDIT RISK AND MAJOR CUSTOMERS

---

| | | |
|:---|:---|:---|
|  | **Contract Assets** | **Contract Assets** |
|  | **March 31,**<br> **2026** | **December 31,**<br> **2025** |
| Customer A | 34% | 36% |
| Customer C | 12% | 13% |
| Total | 46% | 49% |

---

Export sales from the U.S. represented approximately 3% and 2% of net sales for the three months ended March 31, 2026 and 2025, respectively.

**NOTE 3. NET SALES**

**Revenue Recognition**

Revenue under contract manufacturing agreements that was recognized over time, excluding noncash consideration, accounted for 75% and 74% of net sales for the three months ended March 31, 2026 and 2025, respectively. The following tables summarize our net sales by market for the three months ended March 31, 2026 and 2025, respectively:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** |
|  | **Product/ Service Transferred**<br> **Over Time** | **Product Transferred at Point**<br> **in Time** | **Noncash Consideration<sup>1</sup>** | **Total Net Sales by Market** |
| Medical Device | $6679 | $1490 | $742 | $8911 |
| Medical Imaging | 8006 | 1867 | 3 | 9876 |
| Industrial | 3689 | 3018 | 175 | 6882 |
| Aerospace and Defense | 4254 | 356 | 37 | 4647 |
| Total net sales | $22628 | $6731 | $957 | $30316 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** |
|  | **Product/ Service Transferred**<br> **Over Time** | **Product Transferred at Point**<br> **in Time** | **Noncash** <br> **Consideration<sup>1</sup>** | **Total Net Sales by Market** |
| Medical Device | $5772 | $1730 | $568 | $8070 |
| Medical Imaging | 6708 | 1873 | 7 | 8588 |
| Industrial | 4706 | 2132 | 107 | 6945 |
| Aerospace and Defense | 2782 | 478 | 32 | 3292 |
| Total net sales | $19968 | $6213 | $714 | $26895 |

---

<sup>1</sup> Noncash consideration represents material provided by the customer used in the manufacturing of the product.

**Contract Assets**

Contract assets, recorded in the condensed consolidated balance sheets, consist of unbilled amounts related to revenue recognized over time. Significant changes in the contract assets balance during the three months ended March 31, 2026 were as follows:

---

| | |
|:---|:---|
| Balance as of December 31, 2025 | $15184 |
| Increase (decrease) attributed to: |  |
| &nbsp;&nbsp;&nbsp;Amounts transferred over time to contract assets | 22628 |
| &nbsp;&nbsp;&nbsp;Allowance for current expected credit losses |  |
| &nbsp;&nbsp;&nbsp;Amounts invoiced during the period | (21802) |
| Balance outstanding as of March 31, 2026 | $16010 |

---

We expect substantially all the remaining performance obligations for the contract assets recorded as of March 31, 2026 to be transferred to receivables within 90 days, with any remaining amounts to be transferred within 180 days. We bill our customers upon shipment with payment terms of up to 120 days.

**Contract Liabilities**

Contract liabilities, recorded as customer deposits, were $4,672 and $5,386 at March 31, 2026 and December 31, 2025, respectively. Contract liabilities primarily relate to customer prepayments, generally to purchase customer-specific inventory, and billings in advance of the Company satisfying its performance obligations. Revenue recognized during the three months ended March 31, 2026 that was included in the contract liability balance at January 1, 2026 was $565. Changes between periods represent the timing of customer deposits and the satisfaction of performance obligations.

**NOTE 4. FINANCING ARRANGEMENTS**

**Associated Bank Financing Arrangement**

On March 20, 2026, the Company entered into a new Credit and Security Agreement with Associated Bank, National Association, which provides for a revolving credit facility of up to $15,000, subject to a borrowing base based on eligible accounts receivable and inventory, and a $2,200 term loan (the "Associated Facility"). The Associated Facility includes a sublimit of $1,500 for letters of credit and is secured by substantially all of our assets in the United States of America. The Associated Facility matures in March 2029. The Company is required to pay a 25-basis point fee per annum, paid monthly, on the unused portion of the revolving credit facility. The term loan requires monthly principal payments of $37 plus interest. Borrowings under the Associated Facility bear interest, at the Company's option, at a defined base rate derived from the Bank's prime rate, or at one-month or three-month Term Secured Overnight Financing Rate, referred to as SOFR, plus 2.00% in the case of revolving credit borrowings, and plus 2.25% in the case of the term loan. At March 31, 2026, the revolving credit facility and term loan accrued interest at 8.52% and 8.00%, respectively. At March 31, 2026, there was $7,196 outstanding under the revolving credit facility and $3,500 of unused availability. Borrowings under the Associated Facility may be prepaid at any time without penalty. The Associated Facility does not contain prepayment premiums, make-whole provisions, or other features that would require separate accounting as embedded derivatives.

The Associated Facility contains customary affirmative and negative covenants that restrict or limit our ability to incur additional indebtedness, create liens, make investments, sell assets, pay dividends or engage in certain transactions without lender consent. This agreement also requires us to comply with financial covenants, including maintaining a Fixed Charge Coverage Ratio of 1.10 to 1.00, which measures the ratio of EBITDA, as defined to exclude certain other non-cash items, and less unfunded capital expenditures, to fixed charges such as interest as well as debt and capital lease principal payments. The Company was in compliance with all covenants under the Associated Facility as of March 31, 2026.

The Associated Facility agreement includes broad and customary events of default such as non-payment of obligations, breaches of representations or covenants, unauthorized liens, insolvency events, material adverse changes, cross-defaults to other significant indebtedness, and change-of-control triggers. Additional events include unsatisfied judgments, loss of lender lien priority, defaults under material business agreements, impairment of key intellectual property, destruction of collateral, and certain ERISA, hedging, or legal compliance violations. Upon an event of default, including the lender's determination that a material adverse event has occurred, as defined by the Associated Facility agreement, the lender may accelerate all obligations, terminate the commitments, and exercise its full rights and remedies against the collateral.

The Company incurred $290 of debt issuance costs related to the Associated Facility, of which $266 was classified as a long-term asset as of March 31, 2026 as it is related to the revolving facility.

The table below reflects scheduled principal repayments of the term loan. Amounts outstanding under the revolving credit facility, if any, are due at maturity in March 2029.

SCHEDULE OF PRINCIPAL REPAYMENTS OF THE TERM LOAN

---

| | |
|:---|:---|
| **Year** | **Amount** |
| Remainder of 2026 | $330 |
| 2027 | 440 |
| 2028 | 440 |
| 2029 | 990 |
| Thereafter | - |
| Total | $2200 |

---

**Bank Of America Revolver**

On February 29, 2024, we closed on a $15,000 Senior Secured Revolving Line of Credit with Bank of America (the "BOA Revolver"). On February 27, 2026, the Company entered into a Waiver and Amendment. Under the Waiver and Amendment, Bank of America waived certain financial covenant defaults related to the Company's Consolidated Leverage Ratio, Fixed Charge Coverage Ratio, and Consolidated EBITDA for the quarter ended December 31, 2025. The BOA Revolver was fully repaid and terminated on March 20, 2026.

**Interim Funding Agreement**

The Company had an interim funding agreement with a bank related to deposits made on equipment purchases funded through a finance lease when the equipment was received and operational. The equipment was received, and the lease agreements were finalized during the second quarter of 2025. As of March 31, 2026, we have no amounts outstanding on the interim funding agreement for equipment.

**China Financing Agreement**

Our China operation has a financing agreement with China Construction Bank which provides for a line of credit arrangement of 10 million Renminbi (RMB) (approximately $1,400) that expires in August 2026. The Company had $289 outstanding as of March 31, 2026 that is classified as current debt. No amounts were outstanding under this financing arrangement as of December 31, 2025. The agreement does not include material cross-default provisions with the Associated Facility. The variable interest rate as of March 31, 2026 was approximately 4%.

**NOTE 5. LEASES**

We have operating leases for certain manufacturing sites, office space, and equipment. Most leases include the option to renew, with renewal terms that can extend the lease term from one to five years or more. Right-of-use lease assets and lease liabilities are recognized at the commencement date based on the present value of the remaining lease payments over the lease term which includes renewal periods we are reasonably certain to exercise. Our leases do not contain any material residual value guarantees or material restrictive covenants. We have financing leases for certain property and equipment used in the normal course of business.

The components of lease expense were as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| <br>**Lease Cost** | **2026** | **2025** |
| Operating lease cost | $588 | $565 |
| Finance lease interest cost | 14 | 6 |
| Finance lease amortization expense | 62 | 42 |
| Total lease cost | $664 | $613 |

---

Supplemental condensed consolidated balance sheet information related to leases was as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Balance Sheet Location** | **March 31,**<br> **2026** | **December 31,**<br> **2025** |
| **Assets** |  |  |  |
| Finance lease assets | Property and equipment, net | $668 | $714 |
| Operating lease assets | Operating lease assets, net | 6720 | 7016 |
| Total leased assets |  | $7388 | $7730 |
| **Liabilities** |  |  |  |
| *Current* |  |  |  |
| Current operating lease liabilities | Current portion of operating lease obligations | $1309 | $1332 |
| Current finance lease liabilities | Current portion of finance lease obligations | 259 | 274 |
| *Noncurrent* |  |  |  |
| Long-term operating lease liabilities | Long-term operating lease obligations, net of current portion | 6186 | 6476 |
| Long-term finance lease liabilities | Long-term finance lease obligations, net of current portion | 577 | 626 |
| Total lease liabilities |  | $8331 | $8708 |

---

Supplemental condensed consolidated statements of cash flows information for the three months ended March 31, 2026 and 2025 related to leases was as follows:

---

| | | |
|:---|:---|:---|
|  | **March 31,**<br>**2026** | **March 31,**<br>**2025** |
| **Operating Leases** |  |  |
| Cash paid for amounts included in the measurement of lease liabilities | $471 | $433 |

---

Future annual payments of lease liabilities as of March 31, 2026 were as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Operating**<br> **Leases** | **Finance**<br> **Leases** | **Total** |
| Remainder of 2026 | $1406 | $248 | $1654 |
| 2027 | 1580 | 211 | 1791 |
| 2028 | 1569 | 211 | 1780 |
| 2029 | 979 | 196 | 1175 |
| 2030 | 900 | 76 | 976 |
| Thereafter | 3769 | - | 3769 |
| Total lease payments | $10203 | $942 | $11145 |
| Less: imputed interest | (2708) | (106) | (2814) |
| Present value of lease liabilities | $7495 | $836 | $8331 |

---

The lease term and discount rate as of March 31, 2026 and 2025 were as follows:

---

| | | |
|:---|:---|:---|
|  | **March 31,**<br> **2026** | **March 31,**<br> **2025** |
| Weighted-average remaining lease term (years) |  |  |
| &nbsp;&nbsp;&nbsp;Operating leases | 7.0 | 7.6 |
| &nbsp;&nbsp;&nbsp;Finance leases | 3.7 | 3.3 |
| Weighted-average discount rate |  |  |
| &nbsp;&nbsp;&nbsp;Operating leases | 8.1% | 7.8% |
| &nbsp;&nbsp;&nbsp;Finance leases | 6.6% | 5.7% |

---

**NOTE 6. STOCK BASED AWARDS**

Stock-based compensation expense of $126 and $118 for the three months ended March 31, 2026 and 2025, respectively, was reported in the condensed consolidated statements of operations within general and administrative expenses.

*Stock Options*

Under the 2017 Stock Incentive Plan ("2017 Plan"), as amended, there are an aggregate of 775,000 shares authorized for issuance. As of March 31, 2026, there were 35,136 remaining authorized shares available for grant. On March 18, 2026, the Company's Board of Directors approved the 2026 Equity Incentive Plan (the "2026 Plan"), subject to shareholder approval at the upcoming annual meeting in May 2026. The 2026 Plan would succeed the Company's 2017 Stock Incentive Plan and authorize 250,000 shares for various equity- and cash-based awards.

The Company granted 30,000 stock options under the 2017 Plan which vest over 5 years. Weighted average stock option fair value assumptions and the weighted average grant date fair value of stock options granted were as follows:

---

| | |
|:---|:---|
|  | **2026** |
| Stock option fair value assumptions: |  |
| &nbsp;&nbsp;&nbsp;Risk-free interest rate | 3.99% |
| &nbsp;&nbsp;&nbsp;Expected life (years) | 6.2 |
| &nbsp;&nbsp;&nbsp;Dividend yield | -% |
| &nbsp;&nbsp;&nbsp;Expected volatility | 58% |
| Weighted average grant date fair value of stock options granted | $7.14 |

---

Total compensation expense related to stock options was $77 and $54 for the three months ended March 31, 2026, and 2025 respectively. As of March 31, 2026, there was $1,035 of unrecognized compensation related to stock options which will be recognized over a weighted average period of 2.4 years.

Following is a summary of stock option activity as of and for the three months ended March 31, 2026 and 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Shares** | **Weighted-**<br> **Average**<br> **Exercise Price**<br> **Per Share** | **Weighted-**<br> **Average**<br> **Remaining**<br> **Contractual**<br> **Term**<br> **(in years)** | **Aggregate**<br> **Intrinsic Value** |
| Outstanding – December 31, 2024 | 453400 | $6.79 | 5.70 | $1654 |
| Granted |  |  |  |  |
| Exercised | (200) | 9.37 |  |  |
| Forfeited | (4400) | 8.98 |  |  |
| Outstanding – March 31, 2025 | 448800 | $6.77 | 5.45 | $1508 |
| Outstanding – December 31, 2025 | 490182 | $6.91 | 5.14 | $828 |
| Granted | 30000 | 12.19 |  |  |
| Exercised |  |  |  |  |
| Forfeited | (4200) | 9.94 |  |  |
| Outstanding – March 31, 2026 | 515982 | $6.65 | 4.77 | $2584 |
| Exercisable on March 31, 2026 | 331100 | $5.63 | 9.4 | $2180 |

---

*Restricted Stock Units*

 

Total compensation expense related to restricted stock units ("RSUs") was $49 and $64 for the three months ended March 31, 2026 and 2025, respectively. No RSUs were granted during the three-month periods ended March 31, 2026 and 2025. As of March 31, 2026, total unrecognized compensation expense related to the 43,664 outstanding RSUs was $207, which will vest over a weighted average period of 1.0 years. On March 18, 2026 these RSU's were modified to allow full vesting upon a change of control, as defined in the amendment. Management concluded that no incremental compensation cost was required, as the added change-in-control provision did not impact the fair value of the awards at the modification date.

**NOTE 7. NET INCOME (LOSS) PER SHARE DATA**

Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding. Dilutive net income (loss) per common share assumes the exercise and issuance of all potential common stock equivalents in computing the weighted-average number of common shares outstanding using the treasury stock method, unless their effect is anti-dilutive. Basic and diluted weighted average shares outstanding were as follows:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended**<br> **March 31,** | **Three Months Ended**<br> **March 31,** |
|  | **2026** | **2025** |
| Basic weighted average shares outstanding | 2786134 | 2760929 |
| Dilutive effect of outstanding stock options and non-vested restricted stock units<sup>1</sup> | - | - |
| Diluted weighted average shares outstanding | 2786134 | 2760929 |

---

<sup>1</sup> The following items were excluded from the computation of diluted weighted-average shares outstanding as their inclusion would be anti-dilutive:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. For
 the three months ended March 31, 2026, restricted stock units and stock options totaling 602,446 .

b. For
 the three months ended March 31, 2025, restricted stock units and stock options totaling 472,941 .

**NOTE 8. INCOME TAXES**

On a quarterly basis, we estimate what our effective tax rate will be for the full fiscal year and record a quarterly income tax provision based on the anticipated rate. As the year progresses, we refine our estimate based on the facts and circumstances, including discrete events.

Our effective tax rate for the three months ended March 31, 2026 was 84%, compared to 28% for the three months ended March 31, 2025. The primary drivers of the change in the effective tax rate are the differences in pretax book income (loss) by jurisdiction and taxes on foreign entities.

**NOTE 9. SEGMENT INFORMATION**

Our results of operations for the three months ended March 31, 2026 and 2025 represent a single operating and reporting segment referred to as Contract Manufacturing within the EMS industry. The Company operates in the Medical Device, Medical Imaging, Aerospace and Defense, and Industrial markets with over 50% of its net sales coming from the medical-related markets. We strategically direct production between our various manufacturing facilities based on several considerations to best meet our customers' needs. Our plants generate net sales over several of the markets the Company serves. We share resources for sales, marketing, engineering, supply chain, information services, human resources, payroll, and all corporate accounting functions. Our chief operating decision maker (the "CODM") is the Company's President and Chief Executive Officer. The CODM regularly evaluates financial information prepared in accordance with U.S. GAAP on a consolidated basis to assess performance and allocate resources.

The Company's net sales were located as follows:

SCHEDULE OF NET SALES WERE LOCATED

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended**<br> **March 31,** | **Three Months Ended**<br> **March 31,** |
|  | **2026** | **2025** |
| United States | $17464 | $16310 |
| Mexico | 7342 | 6580 |
| China | 5510 | 4005 |
| Total net sales | $30316 | $26895 |

---

The Company's long-lived tangible assets, including the Company's operating lease assets recognized on the condensed consolidated balance sheets were located as follows:

---

| | | |
|:---|:---|:---|
|  | **March 31,**<br> **2026** | **December 31,**<br> **2025** |
| United States | $8727 | $8876 |
| Mexico | 1858 | 2015 |
| China | 1212 | 1328 |
| Total long-lived tangible assets | $11797 | $12219 |

---

**NOTE 10. RESTRUCTURING CHARGES**

During 2024, we recorded restructuring charges of $571 related to the closure and consolidation of our Blue Earth, Minnesota production facility, which was completed in the fourth quarter of 2024. As of December 31, 2024, $154 of facility consolidation expenses related to the Blue Earth closure were accrued and paid in the first quarter of 2025. During the three months ended March 31, 2025, the Company incurred $266 of restructuring charges, in connection with activities related to the Blue Earth facility and additional staff reductions in the first quarter of 2025.

The following table summarizes the related activity for the three months ended March 31, 2025:

---

| | | | |
|:---|:---|:---|:---|
|  | **Facility Consolidation** | **Workforce Reductions** | **Total** |
| December 31, 2024 | $154 | $- | $154 |
| Charges | 31 | 235 | 266 |
| Cash payments | (185) | (235) | (420) |
| March 31, 2025 | $- | $- | $- |

---

We did not record any restructuring charges or restructuring charge activity in the three months ended March 31, 2026.

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

**Overview**

We are a Minnesota, United States based full-service global EMS contract manufacturer in the Medical Device, Medical Imaging, Aerospace and Defense and Industrial markets offering a full range of value-added engineering, technical and manufacturing services and support including project management, design, testing, prototyping, manufacturing, supply chain management and post-market services. Our products are complex electromedical and electromechanical products including medical devices, wire and cable assemblies, printed circuit board assemblies, complex higher-level assemblies and other box builds for a wide range of industries. As of December 31, 2025, we have facilities in Minnesota: Bemidji, Mankato, Milaca and Maple Grove. We closed our facility in Blue Earth, Minnesota in December 2024 and sold this facility in July 2025. We also have facilities in Monterrey, Mexico and Suzhou, China.

Our net sales are derived from complex designed products built to the customers' specifications. The products we manufacture are engineered and designed products that require sophisticated manufacturing support. Quality, on-time delivery, and reliability are of upmost importance. Our goal is to expand and diversify our customer base by focusing on sales and marketing efforts that fit our value-added service, early engagement design, and development strategy. We continue to focus on lean manufacturing initiatives, quality and on-time delivery improvements to increase asset utilization, reduce lead times and provide competitive pricing.

Our strategic investments have positioned us to capitalize on growth opportunities in the medical markets and improve our competitiveness by expanding our global footprint. Our industrial and defense markets are focused on improving our asset utilization and profitability while transforming to a value added, solution-sell business model that supports early engagement, design for manufacturability and rapid prototyping.

All dollar amounts are stated in thousands of U.S. dollars.

**Results of Operations**

*Net Sales.* Net sales for the three months ended March 31, 2026 and 2025 were $30,316 and $26,895, respectively, a comparative period increase of $3,421 or 12.7%. Net sales in the three months ended March 31, 2026 were positively impacted in Aerospace and Defense from the receipt of customer approvals for products transferred from our Blue Earth facility to our Bemidji facility during 2025 as well as manufacturing and plant utilization efficiencies gained related to our 2025 facility optimization. The following is a summary of net sales by our major industry markets:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
|  | **2026** | **2025** | **Increase (Decrease)** | **Increase (Decrease)** |
| Medical Device | $8911 | $8070 | $841 | 10.4% |
| Medical Imaging | 9876 | 8588 | 1288 | 15.0% |
| Industrial | 6882 | 6945 | (63) | (0.9)% |
| Aerospace and Defense | 4647 | 3292 | 1355 | 41.2% |
| **Total net sales** | $30316 | $26895 | $3421 | 12.7% |

---

● Medical Device: Net sales to our medical customers increased $841, or 10.4%, in the three months ended March 31, 2026 as compared with the same period in 2025. The increase was primarily due to the ramp up of production post our 2025 facility optimization.

● Medical Imaging: Net sales to our Medical Imaging customers increased $1,288, or 15.0%, in the three months ended March 31, 2026 as compared with the same period in 2025. The increase was primarily due to higher sales volume to existing customers.

● Industrial: Net sales to our industrial customers remained relatively flat with a decrease of $63, or 0.9%, in the three months ended March 31, 2026 as compared with the same period in 2025.

● Aerospace and Defense: Net sales to our aerospace and defense customers increased $1,355, or 41.2%, in the three months ended March 31, 2026 as compared with the same period in 2025. The increase primarily relates to the positive impact from receipt of customer approvals for products transferred from our Blue Earth facility to our Bemidji facility.

*Backlog.* Our 90-day shipment backlog as of March 31, 2026 was $31,475, an increase of 15.3% from $27,288 at the beginning of the quarter, and a 17.7% increase from March 31, 2025. Our 90-day backlog consists of firm purchase orders we expect to ship in the next 90 days, with any remaining amounts to be shipped within 180 days.

Our total order backlog as of March 31, 2026, was $90,802, representing a 17.4% increase from $77,343 at the beginning of the quarter and a 32.9% increase compared to the same period in the prior year; this year over year growth was primarily driven by an increase in Aerospace and Defense orders.

90-day shipment and total backlog by our major industry markets are as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **March 31, 2026** | **March 31, 2026** | **December 31, 2025** | **December 31, 2025** | **March 31, 2025** | **March 31, 2025** |
|  | **90 Day** | **Total** | **90 Day** | **Total** | **90 Day** | **Total** |
| Medical Device | $10512 | $27332 | $8733 | $27094 | $5735 | $19925 |
| Medical Imaging | 6509 | 9476 | 5725 | 9032 | 7526 | 10020 |
| Industrial | 4842 | 13113 | 4697 | 11404 | 5999 | 10005 |
| Aerospace and Defense | 9612 | 40881 | 8133 | 29813 | 7482 | 28382 |
| **Total backlog** | $31475 | $90802 | $27288 | $77343 | $26742 | $68332 |

---

The 90-day and total backlog as of March 31, 2026 includes orders already recognized in net sales and included in the contract asset value of $16,010.

*Operating Costs and Expenses.*

Net sales, cost of goods sold, gross profit, and operating costs were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** | **Increase/(Decrease)** | **Increase/(Decrease)** |
| Net sales | $30316 | $26895 | $3421 | 12.7% |
| Cost of goods sold | 25614 | 23817 | 1797 | 7.5% |
| Gross profit | 4702 | 3078 | 1624 | 52.8% |
| &nbsp;&nbsp;&nbsp;Gross margin percentage **<sup>(1)</sup>** | 15.5% | 11.4% | 410 bpc<sup>(2)</sup> |  |
| Selling | 1331 | 1184 | 147 | 12.4% |
| &nbsp;&nbsp;&nbsp;% of Net sales | 4.4% | 4.4% |  |  |
| General and administrative | 3014 | 2915 | 99 | 3.4% |
| &nbsp;&nbsp;&nbsp;% of Net sales | 9.9% | 10.8% |  |  |
| Research and development | 310 | 326 | (16) | (4.9)% |
| &nbsp;&nbsp;&nbsp;% of Net sales | 1.0% | 1.2% |  |  |
| Restructuring charges |  | 266 | (266) | (100)% |
| &nbsp;&nbsp;&nbsp;% of Net sales | -% | 0.9% |  |  |
| Operating income (loss) | 47 | (1613) | 1660 | 102.9% |
| &nbsp;&nbsp;&nbsp;% of Net sales | 0.2% | (6.0)% |  |  |

---

*<sup>(1)</sup>* Gross margin percentage is defined as gross profit as a percentage of net sales.

*<sup>(2)</sup>* Basis points change in gross margin percentage.

 

*Gross profit and gross margin percentage.* Gross margin percentage was 15.5% and 11.4% for the three months ended March 31, 2026, and 2025, respectively. The increase in gross margin percentage was the result of improved plant utilization primarily from our restructuring activities and higher sales on a fixed cost base.

*Selling expenses*. Selling expenses, as measured as a percentage of net sales*,* were 4.4% for both the three months ended March 31, 2026, and 2025.

*General and administrative expenses.* General and administrative expenses, as measured as a percentage of net sales, were 9.9% and 10.8% for the three months ended March 31, 2026 and 2025, respectively. This decrease as a percentage of net sales was primarily the result of higher sales on a fixed cost base.

*Restructuring charges*. Restructuring charges were $0 and $266 in the three months ended March 31, 2026 and 2025, respectively. During the first quarter of 2025, we incurred $235 of severance charges for a February 2025 reduction in force to align staffing to our forecasted net sales and $31 of expenses related to our closed Blue Earth facility.

*Operating income (loss).* Operating income was $47 for the three months ended March 31, 2026 or 0.2% of net sales and operating loss was $(1,613) or (6.0)% of net sales for the three months ended March 31, 2025. The improvement was primarily driven by higher gross margin percentage, which increased operating income by $1,234, and higher net sales, which contributed an additional $390.

*Interest expense, net.* Interest expense, net was $256 and $214 for the three months ended March 31, 2026 and 2025, respectively. This increase was driven by the write-off of unamortized debt issuance costs of $88 associated with our prior financing arrangement that was refinanced in the period. Refer to "Liquidity and Capital Resources" for further discussion of financing arrangements.

*Income taxes.* Our effective tax rate for the three months ended March 31, 2026 and 2025 was 84% and 28%, respectively. The primary drivers of the change in the effective tax rate were differences in pretax book income (loss) by jurisdiction and taxes on foreign entities.

**Cash Flow Operating Results**

The following is a summary of cash flow results:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Cash provided by (used in): |  |  |
| &nbsp;&nbsp;&nbsp;Operating activities | $(1561) | $(2930) |
| &nbsp;&nbsp;&nbsp;Investing activities | (228) | (268) |
| &nbsp;&nbsp;&nbsp;Financing activities | 2336 | 3446 |
| Effect of exchange rates on changes in cash and restricted cash | 6 | (2) |
| Net change in cash and restricted cash | $553 | $246 |

---

*Operating Activities.* Cash used in operating activities was $1,561 in the first three months of 2026, compared with $2,930 in the same prior-year period. Significant changes in operating assets and liabilities affecting cash flows during these periods included:

● Cash used by accounts receivable and contract assets was $1,648 in the three months ended March 31, 2026 as compared with cash used of $426 in the same prior-year period. This use of cash is largely due to timing of customer shipments and cash collections in both periods and by an increase in contract assets in the current year period to support future customer shipments.

● Cash used by inventory was $2,610 in the three months ended March 31, 2026 as compared with cash provided of $487 in the prior-year period. The increase in the current-year period cash usage was the result of normal timing variances of inventory purchases and timing of product shipments.

● Cash provided by changes in accounts payable was $1,917 in the current-year period as compared with cash used of $1,441 in the same prior-year period, primarily related to the timing of cash payments.

*Investing Activities.* Cash used in investing activities was $228 in the first three months of 2026, compared with $268 in the same prior-year period, both due from the purchases of property and equipment.

*Financing Activities.* Cash provided by financing activities was $2,336 in the first three months of 2026 and $3,446 in the same prior-year period. The cash provided by financing activities in both periods resulted from the line of credit advances for working capital and operations as well as the term loan borrowing in the first three months of 2026.

**Liquidity and Capital Resources**

We believe that our existing financing arrangements, anticipated cash flows from operations, and cash on hand will be sufficient to satisfy our working capital needs, capital expenditures and debt repayments for the next year from the date of this filing with the Securities and Exchange Commission.

On March 20, 2026, the Company entered into a new Credit and Security Agreement with Associated Bank, National Association, which provides for a revolving credit facility of up to $15,000, subject to a borrowing base based on eligible accounts receivable and inventory in the United States of America ("U.S."), and a $2,200 term loan (the "Associated Facility"). The Associated Facility includes a sublimit of $1,500 for letters of credit and is secured by substantially all of our assets in the U.S. The Associated Facility matures in March 2029. The Company is required to pay a 25-basis point fee per annum, paid monthly, on the unused portion of the revolving credit facility. The term loan requires monthly principal payments of $37 plus interest. Borrowings under the Associated Facility bear interest, at the Company's option, at a defined base rate derived from the Bank's prime rate, or at one-month or three-month Term Secured Overnight Financing Rate, referred to as SOFR, plus 2.00% in the case of revolving credit borrowings, and plus 2.25% in the case of the term loan. At March 31, 2026, the revolving credit facility and term loan accrued interest at 8.52% and 8.00%, respectively. At March 31, 2026, there was $7,196 outstanding under the revolving credit facility and $3,500 of unused availability. Borrowings under the Associated Facility may be prepaid at any time without penalty. The Associated Facility does not contain prepayment premiums, make-whole provisions, or other features that would require separate accounting as embedded derivatives.

The Associated Facility contains customary affirmative and negative covenants that restrict or limit our ability to incur additional indebtedness, create liens, make investments, sell assets, pay dividends or engage in certain transactions without lender consent. This agreement also requires us to comply with financial covenants, including maintaining a Fixed Charge Coverage Ratio of 1.10 to 1.00, which measures the ratio of EBITDA, as defined to exclude certain other non-cash items, and less unfunded capital expenditures, to fixed charges such as interest as well as debt and capital lease principal payments. The Company was in compliance with all covenants under the Associated Facility as of March 31, 2026.

The Associated Facility agreement includes broad and customary events of default such as non-payment of obligations, breaches of representations or covenants, unauthorized liens, insolvency events, material adverse changes, cross-defaults to other significant indebtedness, and change-of-control triggers. Additional events include unsatisfied judgments, loss of lender lien priority, defaults under material business agreements, impairment of key intellectual property, destruction of collateral, and certain ERISA, hedging, or legal compliance violations. Upon an event of default, including the lender's determination that a material adverse event has occurred, as defined by the Associated Facility agreement, the lender may accelerate all obligations, terminate the commitments, and exercise its full rights and remedies against the collateral.

Our ability to comply with these covenants depends in part on our ability to generate sufficient EBITDA and operating cash flow. If our EBITDA or cash flows declines due to any factor, we may not remain in compliance with our financial covenants under the Associated Facility.

**Off-Balance Sheet Arrangements**

We have not engaged in any off-balance sheet activities as defined in Item 303(a)(4) of Regulation S-K.

**Forward-Looking Statements**

Those statements in the foregoing report that are not historical facts are forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;♦ Volatility
 in the marketplace which may affect market supply, demand of our products or currency exchange rates;

♦ Whether
 our existing financing arrangements, anticipated cash flows from operations and cash on hand will be sufficient to satisfy our working
 capital needs, capital expenditures and debt repayments for the next twelve months;

♦ Supply
 chain disruption and unreliability;

♦ Lack
 of supply of sufficient human resources to produce our products;

♦ Increased
 competition from within the EMS industry or the decision of OEMs to cease or limit outsourcing;

♦ Changes
 in the reliability and efficiency of our operating facilities or those of third parties;

♦ Increases
 in certain raw material costs such as copper and oil;

♦ Commodity
 and energy cost instability;

♦ Risks
 related to FDA noncompliance;

♦ The
 loss of a major customer;

♦ General
 economic, financial and business conditions that could affect our financial condition and results of operations;

♦ Increased
 or unanticipated costs related to compliance with securities and environmental regulation;

♦ Disruption
 of global or local information management systems due to natural disaster or cyber-security incident; and

♦ Outbreaks
 of epidemic, pandemic, or contagious diseases, such as the recent novel coronavirus that affect our operations, our customers'
 operations or our suppliers' operations.

The factors identified above are believed to be important factors (but not necessarily all of the important factors) that could cause actual results to differ materially from those expressed in any forward-looking statement made by us. Unpredictable or unknown factors not discussed herein could also have material adverse effects on forward-looking statements. All forward-looking statements included in this Form 10-Q are expressly qualified in their entirety by the forgoing cautionary statements. We undertake no obligation to update publicly any forward-looking statement (or its associated cautionary language) whether as a result of new information or future events.

Please refer to forward-looking statements and risks as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Not applicable.

**ITEM 4. CONTROLS AND PROCEDURES**

**Evaluation of Disclosure Controls and Procedures**

In accordance with Rule 13a-15(b) of the Securities Exchange Act of 1934 (the "Exchange Act"), as of the end of the period covered by this Quarterly Report on Form 10-Q, our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act). These controls and procedures are designed to ensure that information required to be disclosed in the Company's Exchange Act reports is (1) recorded, processed, summarized and reported in a timely manner, and (2) accumulated and communicated to management, including the Company's Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon their evaluation of these disclosure controls and procedures as of the date of the evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures were effective.

**Changes in Internal Control Over Financial Reporting**

There was no change in our internal control over financial reporting during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

**PART II**

**ITEM 1. LEGAL PROCEEDINGS**

We are subject to various legal proceedings and claims that arise in the ordinary course of business.

**ITEM 1A. RISK FACTORS**

We are affected by the risks specific to us as well as factors that affect all businesses operating in a global market. The significant factors known to us that could materially adversely affect our business, financial condition or operating results or could cause our actual results to differ materially from our expectations are described in our annual report on Form 10-K for the fiscal year ended under the heading "Part I – Item 1A. Risk Factors." There have been no material changes in the risk factors from those disclosed in the Annual Report on Form 10-K for the year ended December 31, 2025.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

None.

**ITEM 3. DEFAULTS ON SENIOR SECURITIES**

None.

**ITEM 4. MINE SAFETY DISCLOSURES**

Not applicable.

**ITEM 5. OTHER INFORMATION**

None.

**ITEM 6. EXHIBITS**

---

| | |
|:---|:---|
| **Exhibits** |  |
| 10.1 | [Second Amendment to Lease dated 15th day of May 2024 by and between Sri Management and Consulting LLC, a Minnesota limited liability company, as management agent for the property owners and Nortech Systems, Inc., a Minnesota corporation.](https://www.sec.gov/Archives/edgar/data/722313/000143774924017204/ex_675359.htm) |
| 31.1\* | [Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended.](ex31-1.htm) |
| 31.2\* | [Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended.](ex31-2.htm) |
| 32\* | [Certification of the Chief Executive Officer and Chief Financial Officer, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex32.htm) |
| 101\* | Financial statements from the quarterly report on Form 10-Q for the quarter ended March 31, 2026, formatted in XBRL: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations and Comprehensive Income (Loss), (iii) Condensed Consolidated Statements of Cash Flows, and (iv) the Notes to Condensed Consolidated Financial Statements. |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |

---

\*Filed herewith

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Nortech Systems Incorporated and Subsidiaries | Nortech Systems Incorporated and Subsidiaries |
| Date: May 13, 2026 | by | */s/ Jay D. Miller* |
|  |  | Jay D. Miller |
|  |  | Chief Executive Officer and President |
|  |  | Nortech Systems Incorporated |
| Date: May 13, 2026 | by | */s/ Andrew D. C. LaFrence* |
|  |  | Andrew D. C. LaFrence |
|  |  | Chief Financial Officer and Senior Vice President of Finance |
|  |  | Nortech Systems Incorporated |

---

## Exhibit 31.1

**Exhibit 31.1**

Certification of Chief Executive Officer

Pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934

I, Jay D. Miller, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I
 have reviewed this quarterly report on Form 10-Q of Nortech Systems Incorporated and Subsidiaries;

2. Based
 on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
 to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
 the period covered by this report;

3. Based
 on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
 respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
 this report;

4. The
 registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures
 (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
 Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Designed
 such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
 to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
 within those entities, particularly during the period in which this report is being prepared;

b) Designed
 such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
 supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
 for external purposes in accordance with generally accepted accounting principles;

c) Evaluated
 the effectiveness of the registrant's disclosure controls and procedures and presented in the report our conclusions about
 the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report on such evaluation;
 and

d) Disclosed
 in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's
 most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected,
 or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The
 registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial
 reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing
 the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) All
 significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
 reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information;
 and

b) Any
 fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's
 internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: May 13, 2026 | By: | */s/ Jay D. Miller* |
|  |  | Jay D. Miller |
|  |  | Chief Executive Officer and President |
|  |  | Nortech Systems Incorporated |

---

## Exhibit 31.2

**Exhibit 31.2**

Certification of Chief Financial Officer

Pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934

I, Andrew D. C. LaFrence, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I
 have reviewed this quarterly report on Form 10-Q of Nortech Systems Incorporated and Subsidiaries;

2. Based
 on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
 to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
 the period covered by this report;

3. Based
 on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
 respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
 this report;

4. The
 registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures
 (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
 Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Designed
 such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
 to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
 within those entities, particularly during the period in which this report is being prepared;

b) Designed
 such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
 supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
 for external purposes in accordance with generally accepted accounting principles;

c) Evaluated
 the effectiveness of the registrant's disclosure controls and procedures and presented in the report our conclusions about
 the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report on such evaluation;
 and

d) Disclosed
 in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's
 most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected,
 or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The
 registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial
 reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing
 the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) All
 significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
 reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information;
 and

b) Any
 fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's
 internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: May 13, 2026 | By: | */s/ Andrew D. C. LaFrence* |
|  |  | Andrew D. C. LaFrence |
|  |  | Chief Financial Officer and Senior Vice President of Finance |
|  |  | Nortech Systems Incorporated |

---

## Ex-32

**Exhibit 32**

Written Statement of the Chief Executive Officer

Pursuant to 18 U.S.C. Section 1350

Solely for the purposes of complying with 18 U.S.C. Section 1350, I, the undersigned Jay D. Miller, hereby certify, based on my knowledge, that the Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2026 (the "Report") fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 13, 2026

---

| | |
|:---|:---|
| By: | */s/ Jay D. Miller* |
|  | Jay D. Miller |
|  | Chief Executive Officer and President |
|  | Nortech Systems Incorporated |

---

Written Statement of the Chief Financial Officer

Pursuant to 18 U.S.C. Section 1350

Solely for the purposes of complying with 18 U.S.C. Section 1350, I, the undersigned Andrew D .C. LaFrence, hereby certify, based on my knowledge, that the Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2026 (the "Report") fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 13, 2026

---

| | |
|:---|:---|
| By: | */s/ Andrew D. C. LaFrence* |
|  | Andrew D. C. LaFrence |
|  | Chief Financial Officer and Senior Vice President of Finance |
|  | Nortech Systems Incorporated |

---